ClinicalTrials.gg
TerminatedNCT00298272Updated Sep 28, 2015Results posted

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

A Phase 2 interventional study of IDEC-C2B8 (rituximab) and Placebo in Rheumatoid Arthritis, sponsored by Biogen. Terminated at 18 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-09-28.

Sponsored by Biogen · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decided to end long term extension phase for business reasons unrelated to safety.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
48th of 63
54 · median 159
Started
2006
with 10 others
Phase 2
11 of 63
1 open now
Registered
5th of 63
by date
Lead sponsor
1 of 63
Biogen

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 48th largest by enrollment, is one of 11 that started in 2006, is one of 11 in phase 2, and was the 5th registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary objective of this study was to evaluate the tolerability and safety of rituximab in combination with methotrexate (MTX) and etanercept or adalimumab in participants with active rheumatoid arthritis (RA). The secondary objective was to explore the efficacy of rituximab in combination with MTX and etanercept or adalimumab in participants with active RA.

Read the detailed description

The study consists of 4 parts: screening, treatment, post-treatment, and safety follow-up. Prior to Day 1, participants were discontinued from all disease-modifying anti-rheumatic drugs (DMARDs) except MTX and etanercept or adalimumab. All participants who met eligibility criteria and were enrolled in the trial were randomized to receive 500 mg rituximab or placebo on Day 1 and Day 15. A subset of 18 participants was enrolled initially and followed through Week 12 for safety. The remaining 42 participants were to be enrolled after the last participant in the subset completed Week 12 and the Data Safety Monitoring Board (DSMB) conducted a safety review and approved enrollment of these additional participants. Participants were dosed on Day 1 and Day 15 and followed for 56 weeks, while remaining on their current dose of MTX and etanercept or adalimumab throughout the study. The primary endpoint was assessed at Week 24.

All participants in double-blind treatment, including those who received placebo or rituximab, who met the open label inclusion/exclusion criteria anytime from Week 24 through Week 40, were eligible to enter the open label retreatment phase. These participants received open label rituximab on Day 1 and Day 15 of the retreatment phase, and were followed monthly until Week 24 then every 2 months until Week 56, while remaining on their current dose of MTX and etanercept or adalimumab throughout the study. Participants received 1 course of open label treatment only.

All participants were required to return for safety follow-up (SFU) assessments at Weeks 4, 12, 24, 36, and 48 after withdrawal or completion of the study. Participants whose peripheral CD20+ B cells remained depleted at the end of the SFU periods for the primary and OL portions of the study entered extended safety follow-up (ESFU). Assessments for ESFU were performed at 12-week intervals until peripheral B-cell levels returned to within normal range or baseline level (whichever was lower).

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Must give written . If required by local law, candidates must also authorize the release and use of protected health information (PHI).
  2. Male or female participants, between 18 and 65 years of age, who have a diagnosis of active RA for at least 6 months, diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria for the classification of rheumatoid arthritis (RA).
  3. Must have at least 5 tender and 5 swollen joints at Screening and Day 1.
  4. Must have been treated with etanercept at 50 mg per week (25 mg twice per week or 50 mg once per week) or adalimumab at 40 mg every other week for at least 12 weeks immediately prior to Day 1.
  5. Must have been treated with methotrexate (MTX) greater than or equal to 15 mg per week and less than or equal to 25 mg per week (dose may be as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks.
  6. Must be willing to receive oral folate.
  7. Oral must not exceed 10 mg per day of prednisone (or equivalent dose) and must have been administered at a stable dose for at least 4 weeks prior to Day 1.
  8. Any concomitant non-steroidal antiinflammatory drugs (NSAIDs) must be stable for at least 2 weeks prior to Day 1.
  9. For participants of (males and females), use of a reliable means of (e.g., hormonal contraceptive, patch, intrauterine device, physical barrier) throughout study participation.

    Exclusion Criteria:

    Exclusions Related to RA

  10. Rheumatic disease other than RA, or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis, or Felty's syndrome). Secondary Sjögren's syndrome or secondary limited cutaneous vasculitis with RA is permitted.
  11. Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis.
  12. History of, or current, inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus [SLE], inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease, or any overlap syndrome).
  13. Diagnosis of juvenile idiopathic arthritis, also known as juvenile RA, and/or RA before age 16.

    Exclusions Related to General Health

  14. Any surgical procedure, including bone/joint surgery/synovectomy (including joint fusion or replacement) within 12 weeks prior to baseline or planned within 24 weeks of randomization.
  15. Lack of peripheral venous access.
  16. Pregnancy or breast feeding.
  17. Significant cardiac or pulmonary disease (including obstructive pulmonary disease).
  18. History of chronic heart failure (CHF), SLE-like syndrome, neuropathy or myelitis, optic neuritis, or pancytopenia while on etanercept or adalimumab.
  19. Evidence of significant uncontrolled concomitant disease such as, but not limited to, nervous system, renal, hepatic, endocrine, or gastrointestinal disorders which, in the investigator's opinion, would preclude subject participation.
  20. Primary or secondary immunodeficiency (history of, or currently active), including known history of (HIV) infection.
  21. Known active infection of any kind (excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with IV anti infectives within 4 weeks of Day 1 or completion of oral anti infectives within 2 weeks of Day 1.
  22. History of positive purified protein derivative (PPD) not adequately treated.
  23. History of deep space/tissue infection (e.g., fasciitis, abscess, osteomyelitis) within 52 weeks of Day 1.
  24. History of serious infection or opportunistic infection in the last 2 years (to screen for a chest infection, a chest radiograph will be performed at Screening if one was not performed within 12 weeks prior to Screening).
  25. History of seizures.
  26. History of cancer, including solid tumors, hematologic , and carcinoma in situ (except basal cell and squamous cell carcinoma of the skin that have been excised and cured).
  27. Any neurological (congenital or acquired), vascular, or systemic disorder that might affect any of the efficacy assessments, in particular, joint pain and swelling (e.g., Parkinsons disease, cerebral palsy, diabetic neuropathy).
  28. Currently active alcohol or drug abuse or history of alcohol or drug abuse (as determined by the Investigator) within 1 year prior to Day 1.

    Exclusions Related to Medications

  29. History of a severe allergic or anaphylactic reaction to a biologic agent or known to any component of rituximab or to murine proteins.
  30. Previous treatment with an anti alpha 4 integrin agent or costimulation modulator.
  31. Concurrent treatment with any biologic agent other than etanercept or adalimumab, or disease-modifying anti-rheumatic drug (DMARD) other than MTX. Treatment with any biologic or DMARD except etanercept or adalimumab, and MTX must be discontinued 14 days prior to baseline, except for the following: azathioprine for 28 days; leflunomide for 8 weeks (or 14 days after 11 days of standard cholestyramine or activated charcoal washout).
  32. Previous treatment with any cell depleting therapies, including agents (e.g., Campath [alemtuzumab], anti-CD4, anti-CD5, anti-CD3, anti-CD19, anti CD11a, anti-CD22, B lymphocyte stimulator/B-cell activating factor [BLys/BAFF], and anti-CD20).
  33. Treatment with another investigational drug within 4 weeks prior to Day 1 or 5 half lives of the investigational drug (whichever is the longer).
  34. Receipt of a live/attenuated vaccine within 4 weeks prior to Day 1.
  35. Intra-articular or parenteral glucocorticoids within 4 weeks prior to Day 1.
  36. Intolerance or to IV glucocorticoids.

    Exclusions Related to Laboratory Findings

  37. For women of , a positive serum pregnancy test at screening and/or a positive urine pregnancy test on Day 1.
  38. Positive surface antigen (HBsAg).
  39. Positive hepatitis B core antibody (HBcAb) associated with positive hepatitis B viral DNA (HBV DNA).
  40. Positive antibody.
  41. (AST) or alanine aminotransferase (ALT) >2.5 times .
  42. \<8.0 g/dL.
  43. Levels of immunoglobulin G (IgG) and/or immunoglobulin M (IgM) below 5.0 and 0.4 mg/mL, respectively.
  44. (ANC) \<1500/mL.

    Miscellaneous Exclusions

  45. Current enrollment in any other investigational or other drug study.
  46. Treatment with IV Gamma Globulin or the Prosorba® Column within 6 months of the Screening visit.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Double-blind/Open Label Rituximab

    The double-blind rituximab treatment group received rituximab 500 mg by intravenous (IV) infusion on Day 1 and Day 15. After 24 weeks (primary endpoint completion), participants continued post-treatment follow-up (PTFU) visits through Week 56, and entered a 48-week Safety Follow-Up (SFU). At any time between Week 24 and Week 40 of PTFU, eligible participants could enter the rituximab open label (OL) arm, and "restart" the 56-week treatment/follow-up schedule (rituximab 500 mg by IV infusion on Day 1 and Day 15) prior to the 48-week SFU. Prior to rituximab infusion, participants were premedicated with methylprednisolone 100 mg IV. Participants received folate ≥5 mg weekly. Background therapy (stable dose for the duration of the study) included: a tumor necrosis factor (TNF) inhibitor; either etanercept 50 mg subcutaneous injection (SC) weekly or adalimumab 40 mg SC once every 2 weeks; methotrexate (MTX) 15 to 25 mg by mouth or by intramuscular injection (IM) weekly.

    Biological: IDEC-C2B8 (rituximab) · Drug: Methotrexate · Drug: Etanercept · Drug: Adalimumab · Drug: Methylprednisolone · Dietary Supplement: Folate

  • Other
    Double-blind Placebo/Open Label Rituximab

    The double-blind placebo treatment group received saline solution IV on Day 1 and Day 15. After 24 weeks (primary endpoint completion), participants continued post-treatment follow-up (PTFU) visits through Week 56, and entered a 48-week Safety Follow-Up (SFU). At any time between Week 24 and Week 40 of PTFU, eligible participants could enter the rituximab open label (OL) arm, and "restart" the 56-week treatment/follow-up schedule (rituximab 500 mg by IV infusion on Day 1 and Day 15) prior to the 48-week SFU. Prior to each infusion of placebo, participants were premedicated with methylprednisolone 100 mg IV. Participants received folate ≥5 mg weekly. Background therapy (stable dose for the duration of the study) included: a tumor necrosis factor (TNF) inhibitor; either etanercept 50 mg subcutaneous injection (SC) weekly or adalimumab 40 mg SC once every 2 weeks; methotrexate (MTX) 15 to 25 mg by mouth or by intramuscular injection (IM) weekly.

    Drug: Placebo · Drug: Methotrexate · Drug: Etanercept · Drug: Adalimumab · Drug: Methylprednisolone · Dietary Supplement: Folate

Interventions

  • Participants will receive 500 mg rituximab on Day 1 and Day 15

    Also known as: Rituxan

  • DrugPlacebo

    Participants will receive placebo on Day 1 and Day 15

  • Participants must have been treated with MTX ≥15 mg per week and ≤25 mg per week (dose may have been as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks and was continued for the study duration.

  • Participants must have been treated with etanercept at 50 mg per week (25 mg twice per week or 50 mg once per week).

    Also known as: Enbrel

  • Participants must have been treated with adalimumab at 40 mg every other week for at least 12 weeks immediately prior to Day 1.

    Also known as: Humira

  • Methylprednisolone 100 mg IV was administered by slow infusion to be completed at least 30 minutes prior to each infusion of rituximab or placebo.

  • Dietary supplementFolate

    All subjects also received a stable dose of folate (≥5 mg per week).

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With at Least One Serious Infection Through Week 24

    An infection was considered serious if it required intravenous (IV) antibiotics or met the regulatory definition of a serious adverse event (SAE). An SAE was any event that resulted in death, resulted in a congenital anomaly in a child of a participant in the study, caused or prolonged an inpatient hospitalization, resulted in significant or persistent disability, or was considered by the investigator to be an important medical event that may have required intervention to prevent any of the above-listed outcomes.

    Time frame: Through Week 24

  2. Number of Participants With Any Infections or Any Grade 3/4 Infections Through Week 24

    Infections were defined as adverse events that map to the Medical Dictionary for Regulatory Activities (MedDRA) system organ class (SOC) of "infections and infestations" and also included other infectious events that do not map to this SOC (e.g., cholecystitis, pleurisy, conjunctivitis, acne, tongue ulceration). Participants with multiple infections were calculated only once. The severity of all reported adverse events, including infections, was graded and reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events. This scale defines the severity of an adverse event as follows: Grade 1 = a mild adverse event, Grade 2 = a moderate adverse event, Grade 3 = a severe adverse event, and Grade 4 = a life-threatening or disabling adverse event.

    Time frame: Through Week 24

  3. Maximum Duration of Infections Through Week 24

    Infections were defined as adverse events that map to the Medical Dictionary for Regulatory Activities (MedDRA) system organ class (SOC) of "infections and infestations" and also included other infectious events that do not map to this SOC (e.g., cholecystitis, pleurisy, conjunctivitis, acne, tongue ulceration). For participants with multiple infections, only the infection with the longest duration was included in this analysis.

    Time frame: Week 24

  4. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Through Week 24

    An AE was any sign (including an abnormal laboratory result that the investigator determined to be clinically significant), symptom, or diagnosis/disease that is unfavorable or unintended, that was new, or if pre-existing, worsened in a participant and that did not necessarily have a causal relationship with the treatment. An SAE was any event that resulted in death, resulted in a congenital anomaly in a child of a participant in the study, caused or prolonged an inpatient hospitalization, resulted in significant or persistent disability, or was considered by the investigator to be an important medical event that may have required intervention to prevent any of the above-listed outcomes.

    Time frame: Through Week 24

  5. Number of Participants With Clinically Significant Immunological and Laboratory Assessment Findings

    The following immunological assessments were conducted: autoantibody concentrations for RF, anti-cyclic-citrullinated peptide (CCP) antibody concentrations, quantitative immunoglobulin levels, and lymphocyte assessments of T- and B-cell populations, determined using whole blood expanded fluorescent-activated cell sorter (FACS) analysis. The following laboratory assessments were performed: hemoglobin, hematocrit, red blood cells (RBC), white blood cells (WBC) with differential, and platelet counts; aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, total protein, albumin, total bilirubin, blood urea nitrogen (BUN), uric acid, creatinine, random glucose, potassium, sodium, chloride, calcium, and phosphorous; blood, protein, and glucose (microscopic examination, if abnormal and applicable).

    Time frame: Through Week 24

Secondary outcomes

  1. Proportion of Participants Achieving an American College of Rheumatology 20 (ACR20) Response at Week 24

    An ACR20 response is defined as a 20% reduction in the number of both swollen and tender joints, and a 20% reduction in the score or results of at least 3 of the following 5 core set measurement tools: Patient and physician assessment of patient disease activity (DA) in previous 24 hours on a visual analog scale (VAS, no DA to maximum DA); patient assessment of pain in previous 24 hours on a VAS (none to unbearable); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C reactive protein or, if missing, erythrocyte sedimentation rate.

    Time frame: Week 24

  2. Proportion of Participants Achieving an American College of Rheumatology 50 (ACR50) Response at Week 24

    An ACR50 response is defined as a 50% reduction in the number of both swollen and tender joints, and a 50% reduction in the score or results of at least 3 of the following 5 core set measurement tools: Patient and physician assessment of patient disease activity (DA) in previous 24 hours on a visual analog scale (VAS, no DA to maximum DA); patient assessment of pain in previous 24 hours on a VAS (none to unbearable); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C reactive protein or, if missing, erythrocyte sedimentation rate.

    Time frame: Week 24

  3. Proportion of Participants Achieving an American College of Rheumatology 70 (ACR70) Response at Week 24

    An ACR70 response is defined as a 70% reduction in the number of both swollen and tender joints, and a 70% reduction in the score or results of at least 3 of the following 5 core set measurement tools: Patient and physician assessment of patient disease activity (DA) in previous 24 hours on a visual analog scale (VAS, no DA to maximum DA); patient assessment of pain in previous 24 hours on a VAS (none to unbearable); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C reactive protein or, if missing, erythrocyte sedimentation rate.

    Time frame: Week 24

07

Results

Posted Nov 17, 2010
Limitations and caveats
Sponsor made a business decision to terminate study on 28 July 2011, after completion of the primary endpoint and during the long-term extension phase. One participant was still in extended safety follow-up and was referred for appropriate care.

Participant flow

Participants were enrolled at 17 sites in the United States.

Double-blind Phase
Participant flow — Double-blind Phase
MilestoneDouble-blind/Open Label RituximabDouble-blind Placebo/Open Label Rituximab
Started3618
Safety population3318
Completed to week 243118
Completed to week 5683
Completed2818
Not completed80
Withdrew: Adverse event20
Withdrew: Failure to return20
Withdrew: Protocol violation20
Withdrew: Withdrawal by subject20
Open Label Retreatment Phase
Participant flow — Open Label Retreatment Phase
MilestoneDouble-blind/Open Label RituximabDouble-blind Placebo/Open Label Rituximab
Started2216
Completed to week 242215
Completed to week 561312
Completed1312
Not completed94
Withdrew: Adverse event12
Withdrew: Insufficient therapeutic response21
Withdrew: Failure to return10
Withdrew: Protocol violation21
Withdrew: Withdrawal by subject10
Withdrew: Administrative/other reason20
Safety Follow-up Phase
Participant flow — Safety Follow-up Phase
MilestoneDouble-blind/Open Label RituximabDouble-blind Placebo/Open Label Rituximab
Started2217
Completed1813
Not completed44
Withdrew: Failure to return11
Withdrew: Withdrawal by subject22
Withdrew: Administrative/other reason11

Outcome measures

PrimaryProportion of Participants With at Least One Serious Infection Through Week 24

An infection was considered serious if it required intravenous (IV) antibiotics or met the regulatory definition of a serious adverse event (SAE). An SAE was any event that resulted in death, resulted in a congenital anomaly in a child of a participant in the study, caused or prolonged an inpatient hospitalization, resulted in significant or persistent disability, or was considered by the investigator to be an important medical event that may have required intervention to prevent any of the above-listed outcomes.

Time frame:
Through Week 24
Reported as:
Number · proportion of participants
Proportion of Participants With at Least One Serious Infection Through Week 24
proportion of participantsRituximabPlacebo
Proportion of Participants With at Least One Serious Infection Through Week 240.030.00
SecondaryProportion of Participants Achieving an American College of Rheumatology 20 (ACR20) Response at Week 24

An ACR20 response is defined as a 20% reduction in the number of both swollen and tender joints, and a 20% reduction in the score or results of at least 3 of the following 5 core set measurement tools: Patient and physician assessment of patient disease activity (DA) in previous 24 hours on a visual analog scale (VAS, no DA to maximum DA); patient assessment of pain in previous 24 hours on a VAS (none to unbearable); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C reactive protein or, if missing, erythrocyte sedimentation rate.

Time frame:
Week 24
Reported as:
Number · proportion of participants
Proportion of Participants Achieving an American College of Rheumatology 20 (ACR20) Response at Week 24
proportion of participantsRituximabPlacebo
Proportion of Participants Achieving an American College of Rheumatology 20 (ACR20) Response at Week 240.300.17
SecondaryProportion of Participants Achieving an American College of Rheumatology 50 (ACR50) Response at Week 24

An ACR50 response is defined as a 50% reduction in the number of both swollen and tender joints, and a 50% reduction in the score or results of at least 3 of the following 5 core set measurement tools: Patient and physician assessment of patient disease activity (DA) in previous 24 hours on a visual analog scale (VAS, no DA to maximum DA); patient assessment of pain in previous 24 hours on a VAS (none to unbearable); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C reactive protein or, if missing, erythrocyte sedimentation rate.

Time frame:
Week 24
Reported as:
Number · proportion of participants
Proportion of Participants Achieving an American College of Rheumatology 50 (ACR50) Response at Week 24
proportion of participantsRituximabPlacebo
Proportion of Participants Achieving an American College of Rheumatology 50 (ACR50) Response at Week 240.120.06
SecondaryProportion of Participants Achieving an American College of Rheumatology 70 (ACR70) Response at Week 24

An ACR70 response is defined as a 70% reduction in the number of both swollen and tender joints, and a 70% reduction in the score or results of at least 3 of the following 5 core set measurement tools: Patient and physician assessment of patient disease activity (DA) in previous 24 hours on a visual analog scale (VAS, no DA to maximum DA); patient assessment of pain in previous 24 hours on a VAS (none to unbearable); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C reactive protein or, if missing, erythrocyte sedimentation rate.

Time frame:
Week 24
Reported as:
Number · proportion of participants
Proportion of Participants Achieving an American College of Rheumatology 70 (ACR70) Response at Week 24
proportion of participantsRituximabPlacebo
Proportion of Participants Achieving an American College of Rheumatology 70 (ACR70) Response at Week 240.000.00
PrimaryNumber of Participants With Any Infections or Any Grade 3/4 Infections Through Week 24

Infections were defined as adverse events that map to the Medical Dictionary for Regulatory Activities (MedDRA) system organ class (SOC) of "infections and infestations" and also included other infectious events that do not map to this SOC (e.g., cholecystitis, pleurisy, conjunctivitis, acne, tongue ulceration). Participants with multiple infections were calculated only once. The severity of all reported adverse events, including infections, was graded and reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events. This scale defines the severity of an adverse event as follows: Grade 1 = a mild adverse event, Grade 2 = a moderate adverse event, Grade 3 = a severe adverse event, and Grade 4 = a life-threatening or disabling adverse event.

Time frame:
Through Week 24
Reported as:
Number · participants
Number of Participants With Any Infections or Any Grade 3/4 Infections Through Week 24
participantsDouble-blind/Open Label RituximabDouble-blind Placebo/Open Label Rituximab
Any Infection1811
Any Grade 3/4 Infection30
PrimaryMaximum Duration of Infections Through Week 24

Infections were defined as adverse events that map to the Medical Dictionary for Regulatory Activities (MedDRA) system organ class (SOC) of "infections and infestations" and also included other infectious events that do not map to this SOC (e.g., cholecystitis, pleurisy, conjunctivitis, acne, tongue ulceration). For participants with multiple infections, only the infection with the longest duration was included in this analysis.

Time frame:
Week 24
Reported as:
Mean · days
Maximum Duration of Infections Through Week 24
daysDouble-blind/Open Label RituximabDouble-blind Placebo/Open Label Rituximab
Maximum Duration of Infections Through Week 2412.6 ± 9.614.5 ± 5.2
PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Through Week 24

An AE was any sign (including an abnormal laboratory result that the investigator determined to be clinically significant), symptom, or diagnosis/disease that is unfavorable or unintended, that was new, or if pre-existing, worsened in a participant and that did not necessarily have a causal relationship with the treatment. An SAE was any event that resulted in death, resulted in a congenital anomaly in a child of a participant in the study, caused or prolonged an inpatient hospitalization, resulted in significant or persistent disability, or was considered by the investigator to be an important medical event that may have required intervention to prevent any of the above-listed outcomes.

Time frame:
Through Week 24
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Through Week 24
participantsDouble-blind/Open Label RituximabDouble-blind Placebo/Open Label Rituximab
Any AE3115
Any SAE20
PrimaryNumber of Participants With Clinically Significant Immunological and Laboratory Assessment Findings

The following immunological assessments were conducted: autoantibody concentrations for RF, anti-cyclic-citrullinated peptide (CCP) antibody concentrations, quantitative immunoglobulin levels, and lymphocyte assessments of T- and B-cell populations, determined using whole blood expanded fluorescent-activated cell sorter (FACS) analysis. The following laboratory assessments were performed: hemoglobin, hematocrit, red blood cells (RBC), white blood cells (WBC) with differential, and platelet counts; aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, total protein, albumin, total bilirubin, blood urea nitrogen (BUN), uric acid, creatinine, random glucose, potassium, sodium, chloride, calcium, and phosphorous; blood, protein, and glucose (microscopic examination, if abnormal and applicable).

Time frame:
Through Week 24
Reported as:
Number · participants
Number of Participants With Clinically Significant Immunological and Laboratory Assessment Findings
participantsDouble-blind/Open Label RituximabDouble-blind Placebo/Open Label Rituximab
Number of Participants With Clinically Significant Immunological and Laboratory Assessment Findings00

Adverse events

Collected over For Double-Blind Rituximab and Double-Blind Placebo reporting groups, nonserious AE data and SAE data are presented through the Week 24 treatment phase (primary endpoint completion). See Additional Description (below) for Cumulative Rituximab time frame.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind Rituximab—2/33 (6.1%)31/33 (93.9%)
Double-Blind Placebo—0/18 (0%)15/18 (83.3%)
Cumulative Rituximab—8/49 (16.3%)48/49 (98%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventDouble-Blind RituximabDouble-Blind PlaceboCumulative Rituximab
Arthritis InfectiveInfections and infestations0/330/184/49
Coronary Artery OcclusionCardiac disorders1/330/181/49
PneumoniaInfections and infestations1/330/181/49
CellulitisInfections and infestations0/330/181/49
OsteomyelitisInfections and infestations0/330/181/49
NeutropeniaBlood and lymphatic system disorders0/330/181/49
DizzinessNervous system disorders0/330/181/49
HeadacheNervous system disorders0/330/181/49
Interstitial Lung DiseaseRespiratory, thoracic and mediastinal disorders0/330/181/49
Impaired Gastric EmptyingGastrointestinal disorders0/330/181/49
Most frequent other events
Showing 10 of 205
Most frequent other events
EventDouble-Blind RituximabDouble-Blind PlaceboCumulative Rituximab
Upper respiratory tract infectionInfections and infestations6/335/1815/49
Rheumatoid arthritisMusculoskeletal and connective tissue disorders3/333/1814/49
SinusitisInfections and infestations3/333/1814/49
HeadacheNervous system disorders3/332/188/49
NauseaGastrointestinal disorders5/332/187/49
Urinary tract infectionInfections and infestations2/331/186/49
ArthralgiaMusculoskeletal and connective tissue disorders3/332/186/49
PruritusSkin and subcutaneous tissue disorders4/330/184/49
FatigueGeneral disorders4/330/185/49
Edema peripheralGeneral disorders3/332/185/49

Baseline characteristics

Safety Population

Age, Continuous
Age, Continuous(Years)Double-blind/Open Label RituximabDouble-blind Placebo/Open Label RituximabTotal
Mean49.7 ± 12.150.4 ± 11.450.0 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Double-blind/Open Label RituximabDouble-blind Placebo/Open Label RituximabTotal
Female281745
Male516
Years since rheumatoid arthritis (RA) diagnosis
Years since rheumatoid arthritis (RA) diagnosis(Years)Double-blind/Open Label RituximabDouble-blind Placebo/Open Label RituximabTotal
Mean10.3 ± 6.710.7 ± 7.510.5 ± 6.9
Number of Prior Tumor Necrosis Factor (TNF) Inhibitors
Number of Prior Tumor Necrosis Factor (TNF) Inhibitors(participants)Double-blind/Open Label RituximabDouble-blind Placebo/Open Label RituximabTotal
1321850
2101
C-Reactive Protein
C-Reactive Protein(mg/dL)Double-blind/Open Label RituximabDouble-blind Placebo/Open Label RituximabTotal
Mean0.97 (0.0 to 6.3)0.83 (0.1 to 3.3)0.92 (0.0 to 6.3)
Swollen and Tender Joints
Swollen and Tender Joints(Joint counts)Double-blind/Open Label RituximabDouble-blind Placebo/Open Label RituximabTotal
Swollen joints16.9 (5 to 43)14.2 (6 to 30)16.0 (5 to 43)
Tender joints25.6 (5 to 56)22.8 (9 to 63)24.6 (5 to 63)
08

Study locations

18 sites
  • Research Site
    Huntsville, Alabama 35801, United States
  • Research Site
    Paradise Valley, Arizona 85253, United States
  • Research Site
    Palm Desert, California 92260, United States
  • Research Site
    Jupiter, Florida 33458, United States
  • Research Site
    Sarasota, Florida 34239, United States
  • Research Site
    Boise, Idaho 83702, United States
  • Research Site
    Kalamazoo, Michigan 49048, United States
  • Research Site
    St. Louis, Missouri 63141, United States
  • Research site
    Chardon, Ohio 44024, United States
  • Research Site
    Mayfield Village, Ohio 44143, United States
  • Research Site
    Oklahoma City, Oklahoma 73103, United States
  • Research Site
    Tulsa, Oklahoma 74135, United States
  • Research Site
    Duncansville, Pennsylvania 16635, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Houston, Texas 77074, United States
  • Research Site
    San Antonio, Texas 78217, United States
  • Research Site
    Salt Lake City, Utah 84132, United States
  • Research Site
    Burlington, Vermont 05401, United States
09

References and documents

Publications

  • Greenwald MW, Shergy WJ, Kaine JL, Sweetser MT, Gilder K, Linnik MD. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial. Arthritis Rheum. 2011 Mar;63(3):622-32. doi: 10.1002/art.30194. PubMed 21360491 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Apr 2009 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2006
First posted
Mar 2, 2006
Start
May 2006
Primary completionActual
Apr 2009
CompletionActual
Jul 2011
Results first posted
Nov 17, 2010
Last update
Sep 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00298272
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Mar 2, 2006
Start date
May 2006
Primary completion
Apr 2009
Completion
Jul 2011
Results posted
Nov 17, 2010
Last update
Sep 28, 2015

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion